The HOPE4MCI study: AGB101 treatment reduces entorhinal cortex atrophy in patients with amnestic mild cognitive impairment due to Alzheimer’s Disease who are ApoE-4 non-carriers

levetiracetam low dose (AGB101) - AgeneBio

Nisha Rani, PhD1; Richard Mohs, PhD2; Michela Gallagher, PhD2,3; Arnold Bakker, PhD1,4

Jun 20, 2024